Skip to content

Batch information on every product pageTHC < 0.3%Shipped from France10% off when you sign up

Research tools

ABX-1431Also known as elcubragistat

A covalent MAGL inhibitor: it raises 2-AG, with no demonstrated clinical efficacy.

Unscheduled
Level of detail

Harm-reduction warning

No characterised human dose: animal / in vitro data only. Effect profile, safety margin and acute toxicity are not documented in human clinical practice. Extremely potent compound: severe effects, seizures and deaths reported in the literature.

C₂₀H₂₂F₉N₃O₂

CAS 1446817-84-0

Family
ECS pharmacological toolEnzyme inhibitor
Molar mass
507.40 g/mol

Updated on

In plain terms

ABX-1431, also called elcubragistat, is a laboratory molecule developed by pharmaceutical companies: it does not come from hemp and is not found in any consumer product. It blocks the enzyme that destroys 2-AG, a cannabinoid the body makes itself, which raises its level in the brain. In a 12-week controlled trial in adults with Tourette syndrome, it showed no efficacy on tics; it is not marketed.

Receptors and activity

Target network

MAGLInhibitorIC50 = 14 nM · humanPC3 cell lysates, activity-based protein profiling
  • Blocks or inhibits

The lower the cited value, the closer the target sits to ABX-1431: one ring per factor of 100. A target with no measured value stays on the edge.

Where these targets live

Where each target has been found in humans, according to the cited studies. The map shows the target, not an effect of ABX-1431.

Brain, side view
Body, front view
Blood

MAGLMAGL found in 5 regions of the body

  1. CortexdenseHighest PET signal in the cerebral cortex1
  2. Basal gangliapresentModerate levels in the putamen1
  3. HippocampuspresentAxon terminals in the hippocampus2
  4. Adipose tissuepresentPresent in subcutaneous adipose tissue3
  5. Immune cellspresentRNA enhanced in blood monocytes4

Map sources

  1. Takahata K et al. First-in-human in vivo imaging and quantification of monoacylglycerol lipase in the brain: a PET study with (18)F-T-401. Eur J Nucl Med Mol Imaging, 2022 (new tab)
  2. Ludányi A et al. Complementary synaptic distribution of enzymes responsible for synthesis and inactivation of the endocannabinoid 2-arachidonoylglycerol in the human hippocampus. Neuroscience, 2011 (new tab)
  3. Spoto B et al. Human adipose tissue binds and metabolizes the endocannabinoids anandamide and 2-arachidonoylglycerol. Biochimie, 2006 (new tab)
  4. Human Protein Atlas. MGLL expression summary (new tab)

Cited values

  1. MAGLInhibitorIC50 = 14 nM · human64 out of 100

    Cisar et al., J Med Chem 2018 (ChEMBL values from the document) (new tab) · PC3 cell lysates, activity-based protein profiling

  2. ABHD6InhibitorIC50 = 2.7 µM · human26 out of 100

    Cisar et al., J Med Chem 2018 (ChEMBL values from the document) (new tab) · PC3 cell lysates

  3. FAAHInhibitorno measured value cited
Bar length follows the measured value (Ki, Kd, EC50 or IC50), on one scale shared by every entry, from 100 µM to 0.1 nM. A target with no cited value has no bar.

Pharmacology

Elcubragistat is a hexafluoroisopropyl carbamate that irreversibly inhibits monoacylglycerol lipase (MAGL or MGLL), the enzyme responsible for breaking down 2-arachidonoylglycerol (2-AG) (Cisar et al. 2018). No intrinsic affinity for CB1 or CB2 is reported: its effects would proceed through accumulation of 2-AG, the endogenous CB1 agonist. Activity-based protein profiling shows marked selectivity among serine hydrolases, with an IC50 of 14 nM on human MGLL against 2.7 µM on ABHD6 and more than 10 µM on FAAH. In rodents, inhibition of brain MGLL occurs at doses of 0.5 to 1.4 mg/kg (ED50), accompanied by a rise in brain 2-AG and a reduction in pain behaviour in the rat formalin test (Cisar et al. 2018). In humans, a phase 1b crossover study in 20 adults with Tourette syndrome showed a reduction in tics on some scales after a single dose (Müller-Vahl et al. 2022), but the 12-week controlled trial in 49 adults showed no efficacy: the difference in the total tic score at week 8 was 3.0 points in favour of placebo (Müller-Vahl et al. 2021). The molecule remains a pharmacological tool of the endocannabinoid system, with no established clinical efficacy and no marketing authorisation.

Key sources.

History

Source
A wholly synthetic molecule with no natural occurrence: it exists neither in cannabis, nor in any other plant, nor in the human body. It was designed in a pharmaceutical laboratory as a tool for studying the endocannabinoid system, then developed as an investigational medicine. It is present in no consumer product.

Origin

Research tool

No biosynthetic pathway: the molecule comes from no living organism. It is a hexafluoroisopropyl carbamate carried by an N-benzylated piperazine, assembled by organic synthesis.

Classification

Family, origin and source verification

Family

ECS pharmacological tool › Enzyme inhibitor

Verification

Classification, sources and binding values checked on 20 October 2026; text read against its sources and Wikipedia.

Wikipedia (English)

Elcubragistat (new tab)

Article paired by the molecule's structure (InChIKey), revision read on 19 October 2026. Read as a second opinion, never cited as a source.

References

  1. Cisar JS et al., Identification of ABX-1431, a Selective Inhibitor of Monoacylglycerol Lipase and Clinical Candidate for Treatment of Neurological Disorders, J Med Chem 2018 (new tab)PMID 30067909
  2. Müller-Vahl KR et al., Monoacylglycerol Lipase Inhibition in Tourette Syndrome: A 12-Week, Randomized, Controlled Study, Mov Disord 2021 (new tab)PMID 34117788
  3. Müller-Vahl KR et al., Endocannabinoid Modulation Using Monoacylglycerol Lipase Inhibition in Tourette Syndrome: A Phase 1 Randomized, Placebo-Controlled Study, Pharmacopsychiatry 2022 (new tab)PMID 34847610
  4. Heins MS et al., Neurochemical in vivo microdialysis and postmortem tissue analysis of amygdala endocannabinoid levels after MAGL- and FAAH-inhibition in rodents, Neurochem Int 2025 (new tab)PMID 40494414
  5. Anderson LL et al., The endocannabinoid system impacts seizures in a mouse model of Dravet syndrome, Neuropharmacology 2022 (new tab)PMID 34822817
  6. ChEMBL, elcubragistat record CHEMBL3945728 (MGLL, ABHD6, FAAH activity data) (new tab)
  7. PubChem, compound CID 71657619 (elcubragistat) (new tab)
  8. ClinicalTrials.gov NCT03625453, phase 2 trial of ABX-1431 in Tourette syndrome (new tab)
  9. ClinicalTrials.gov NCT05201092, carbon-14 mass balance study of Lu AG06466 in healthy humans (new tab)
  10. ClinicalTrials.gov NCT04405323, effect of CYP3A4 inhibition by itraconazole on Lu AG06466 (new tab)

Identifiers

Names

Common name
ABX-1431 (elcubragistat)
IUPAC name
1,1,1,3,3,3-hexafluoropropan-2-yl 4-[[2-pyrrolidin-1-yl-4-(trifluoromethyl)phenyl]methyl]piperazine-1-carboxylate
Other names
ABX1431 · ABX-1431 · elcubragistat · Lu AG06466 · Lu-AG06466

Identifiers

Formula
C₂₀H₂₂F₉N₃O₂
CAS
1446817-84-0
PubChem CID
71657619(new tab)
InChIKey
SQZJGTOZFRNWCX-UHFFFAOYSA-N
SMILES
C1CCN(C1)C2=C(C=CC(=C2)C(F)(F)F)CN3CCN(CC3)C(=O)OC(C(F)(F)F)C(F)(F)F

Machine-readable entry (JSON)

LLM ingestion format: a structured superset of the entry (identifiers, binding, versioned legal status). Full corpus.